DEXCOM INC

Dexcom’s Q2 2026 earnings beat, driven by G7 sales and margin gains, boosts 2026 revenue outlook to $5.18‑$5.25 B and lifts analyst targets.

Dexcom’s Q2 2026 earnings surpass expectations, with revenue up 13%, margins hitting 25.1% and a new $5.2‑$5.3 bn revenue outlook, driving a fresh growth narrative.

Dexcom reports Q2 2026 earnings that beat expectations, boosting revenue outlook and stock price thanks to strong sales of its continuous glucose monitoring systems.

Dexcom’s steady growth, G7 CGM upgrades, and new Spain market ties signal strong earnings ahead—investors see a resilient diabetes care leader ready to expand.

Dexcom’s CGM tech proves reliable in a Swiss insulin‑patch pilot, delivering accurate real‑time glucose data with no failures – a key step for integrated diabetes care.

Dexcom’s Q2/Q3 2025 earnings reveal steady revenue growth, margin improvement, and robust R&D, but investor sentiment warns of pricing, reimbursement, and competition risks.

Dexcom’s quiet institutional selling, amid a booming CGM market, raises questions before its Q1 2026 earnings—will the stock’s growth momentum hold or shift?

Dexcom’s new Eversense 365 CGM shows year‑long glycemic control, driving stock gains and highlighting its role in diabetes care innovation and global expansion.

Explore how Dexcom’s 15‑day CGM, Medicare expansion, and AI features are reshaping diabetes care within the booming digital‑biomarker market.

Dexcom’s recent earnings miss spiked a sharp share‑price drop, but long‑term CGM growth and historic returns hint the stock may still be undervalued and worth watching.